Pregled bibliografske jedinice broj: 392409
Angiogenesis and inhibition.
Angiogenesis and inhibition. // Paediatr Croat 2009 ; 53(Suppl 2):109.
Dubrovnik, Hrvatska; Cavtat, Hrvatska, 2009. str. 109-109 (predavanje, domaća recenzija, sažetak, ostalo)
CROSBI ID: 392409 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Angiogenesis and inhibition.
Autori
Čulić, Srđana
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Izvornik
Paediatr Croat 2009 ; 53(Suppl 2):109.
/ - , 2009, 109-109
Skup
8th Balcan Meeting on Human Genetics
Mjesto i datum
Dubrovnik, Hrvatska; Cavtat, Hrvatska, 14.05.2009. - 17.05.2009
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Domaća recenzija
Ključne riječi
angiogenesis; inhibition
Sažetak
Angiogenesis leads in formation of blood vessels and may be fisiologic or abnormal. Fisiological angionenesis is esential for vound healing and in embriogenesis. Abnormal angiogenesis is required for a tumor to growth and metastasis and is stimulated by hipoxia in tumor. Angiogenesis is regulated through a balance of pro– and anti-angiogenic factors. Scientiests work to find the best agents that can block the development of blood vessels in tumors and blocade the tumor growth and metastasis. The vascular endothelial growth factor family (VEGF) of ligands and its receptors play a critical role in regulation of fiziologic and abnormal angiogenesis. VEGF enhanced expression in individuals with malignant disease indicates a bad progosis. The cognition of anti-VEGF factors suggest that thay may have therapeutic potential for prevention of tumor growth and metastasis. Anti-angiogenesis drugs act where new blood vessels are forming and this treatment is systemic. Chemotherapy and anti-angiogenesis drugs can be given together as strong attack against cancer. Natural angiogenesis inhibitors endostatin, tumstatin, and thrombospondin-1 can have effect on the progression of tumors. The people with Down syndrome have exceptionally low rates of most kinds of cancer having a 1.7-fold higher level of endostatin in the blood. Protein encoded on chromosome 21, Down syndrome critical region 1 (DSCR-1), can block new blood vessel formation acting as an inhibitor of signaling pathways related to cell growth and migration in endothelial cells. Further investigations of the antiangiogenic pathway and its relation to tumor inhibition is essential and Down syndrome is a good model.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus